Skip to content

PolitiKit

Lobbying by Vertex Pharmaceuticals (Canada) Inc.: its registrations, its lobbyists, the bills it has named and every meeting it has reported with federal office holders since November 2021.

← Lobbying

Client of a consultant lobbyist

Vertex Pharmaceuticals (Canada) Inc.

Meetings this Parliament
0
With MPs
0
Since Nov 2021
1
Active registrations
1

Most recent reported meeting: Jul 4, 2023.

Registrations in effect

Consultant In effect since Aug 14, 2026

Consultant William Dempster of 3Sixty Public Affairs Inc.

Consultant lobbyists

  • William Dempster Former public office holder

    Formerly Assistant, Office of the Hon. Irwin Cotler, MP, House of Commons (2002–2003)

Institutions they may lobby: Finance Canada (FIN), Global Affairs Canada (GAC), Health Canada (HC), House of Commons, Innovation, Science and Economic Development Canada (ISED), Justice Canada (JC), Patented Medicine Prices Review Board (PMPRB), Prime Minister's Office (PMO), Privy Council Office (PCO), Public Health Agency of Canada (PHAC), Senate of Canada, Treasury Board Of Canada Secretariat (TBS)

What they're lobbying on (8)
  • Adoption of Bill S-201, An Act respecting a national framework on sickle cell disease, to discuss measures and initiatives to improve care and treatment of Canadians affected by sickle cell disease and increase public awareness of the disease.
  • Implementation of Canada's action plan for pain and federal initiatives related to pain management.
  • Implementation of the the Pharmacare Act and the National Strategy for Drugs for Rare Diseases Implementation of the National Strategy for Drugs for Rare Disease, and other policies or programs related to rare diseases
  • Regulatory amendments and/or guidelines related to the Food and Drugs Act Regulations and Health Canada to implement an orphan drug regulatory framework.
  • Innovation, Science and Economic Development Canada and Innovation Agenda, Science and Technology Strategy, or other Government policy or program initiatives to support research and development activities and attract investments in Canada, including the Biomanufacturing and Life Sciences Strategy
  • Regulations, guidelines, policies and programs related to regulatory and reporting functions of the Patented Medicine Prices Review Board
  • Enhancement to Canada's regulatory and funding environment for new medicines, including Health Canada authorizations of medicines and framework for clinical trials, health technology assessment processes, reimbursement negotiations and funding decisions.
  • Federally-funded Public Drug Plans, with respect to reimbursement for drug products for federal plan beneficiaries.

Registration 778465-355796-14. Look it up in the official Registry

Reported meetings

Spreadsheet

  • Reported by William Dempster · Consultant

    • Ritu Banerjee · Assistant Deputy Minister, Innovation, Science and Economic Development Canada (ISED)

    Health

    Official report

From the Office of the Commissioner of Lobbying's open data, published November 5, 2026. Reports cover oral, arranged meetings with designated public office holders since November 22, 2021; lobbyists file them by the 15th of the following month. Names of MPs are matched to the current House of Commons, and bills are linked when the lobbyist's own description makes clear which bill it means. Contains information licensed under the Open Data Licence Agreement — Office of the Commissioner of Lobbying. Licence. PolitiKit is independent and is not endorsed by the Commissioner of Lobbying.